Современные методы лечения резистентных к внутривенным иммуноглобулинам пациентов с диагнозом «Болезнь Кавасаки» (обзор литературы)
DOI:
https://doi.org/10.15574/SP.2017.86.120Ключевые слова:
болезнь Кавасаки, внутривенный иммуноглобулин, резистентностьАннотация
В статье приведен обзор литературы относительно тактики лечения болезни Кавасаки у детей, резистентных к стандартному лечению внутривенными иммуноглобулинами, введенными в дозе 2 г/кг, и аспирином в дозе 30 мг/кг/день.
Библиографические ссылки
Berezhnyi VV, Sovtus KhM, Bondarets YuI. (2017). Khvoroba Kavasaki u ditei. Osoblyvosti diahnostyky ta likuvannia (lektsiia). Sovremennaia pedyatryia. 3(83): 38—44.
Berezhnoy V. (2015). Effektivnost ispolzovaniya immunobiologicheskogo preparata Etanertsept u detey s revmatoidnyim artritom. Sovremennaya pediatriya. 1(65): 72—82; doi 10.15574/SP.2015.65.72
Yokota S, Nishioka K. (2017). Poslednie dostizheniya pediatricheskoy revmatologii v Yaponii: provospalitelnyie tsitokinyi kak terapevticheskaya mishen pri bolezni Kavasaki, yuvenilnom idiopaticheskom artrite i kriopirin-assotsiirovannom periodicheskom sindrome. RMZh. 5: 380—386.
Maydannik VG, Mityuraeva-Korneyko IA. (2015). Bolezn Kavasaki v detskom vozraste. Nauchnoe izdanie. — Kiev: Logos: 293—295.
Newburger JW, Takahashi M, Gerber MA et al. (2004). Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 110: 2747. https://doi.org/10.1161/01.CIR.0000145143.19711.78; PMid:15505111
Mori M, Imagawa T, Hara R et al. (2012). Efficacy and limitation of Infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: Report of an open-label cases series. J Rheumatol. 39: 864—7. https://doi.org/10.3899/jrheum.110877; PMid:22337241
Kobayashi T, Saji T, Otani T et al. (2012). Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 379: 1613—1620. https://doi.org/10.1016/S0140-6736(11)61930-2
Mori M, Imagawa T, Katakura S et al. (2004). Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol. 14(1): 43—7. https://doi.org/10.3109/s10165-003-0264-3; PMid:17028804
Ohashi R, Fukazawa R, Watanabe M et al. (2013). Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents. Int J Vasc Med. 2013: 43141. https://doi.org/10.1155/2013/543141; PMid:23606968 PMCid:PMC3626397
Burns JC, Best BM, Mejias A et al. (2008). Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Pediatr. 153: 833—8. https://doi.org/10.1016/j.jpeds.2008.06.011; PMid:18672254 PMCid:PMC2856847
Rodriguez-Gonzalez M, Matamala-Morillo MA, Segado-Arenas A. (2014). Infliximab as rescue therapy in refractory Kawasaki disease. Ann Pediatr Cardiol. 7(1): 74—75. https://doi.org/10.4103/0974-2069.126578; PMid:24701096 PMCid:PMC3959072
Choueiter NF, Olson AK, Shen DD, Portman MA. (2010). Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr. 157(6): 960—966. https://doi.org/10.1016/j.jpeds.2010.06.014; PMid:20667551 PMCid:PMC2970727
Newburger JW, Sleeper LA, McCrindle BW et al. (2007). Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 356: 663—675. https://doi.org/10.1056/NEJMoa061235; PMid:17301297
Hashino K, Ishii M, Iemura M et al. (2001). Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 43: 211—217. https://doi.org/10.1046/j.1442-200x.2001.01373.x; PMid:11380911
